Skip to main content
OpenTrials
Completed

NCT Number: NCT04182815

Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung

This study is designed to evaluate clinical safety and diagnostic accuracy of the robotic-assisted bronchoscopy with biopsy performed with the Monarch™ Endoscopy Platform in a broad range of patients with pulmonary lesions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Health Network, Toronto, Ontario, Canada

Loading trial locations.

About this study

Despite technological advancements in guided bronchoscopy such as electromagnetic navigation bronchoscopy and radial probe endobronchial ultrasound, successful biopsy of peripheral pulmonary lesions remains a challenge due to a number of factors, one of which may be the ability to gain access to peripheral lesions due to the size and maneuverability of conventional bronchoscopes. The diagnostic yield of conventional bronchoscopic approaches for peripheral lesions remains suboptimal.

A novel robotic assisted bronchoscopy procedure now exists for patients with lung nodules. This procedure is performed using the Monarch™ platform (Auris Health, Inc., Redwood City, CA). This study is expected to enroll up to 1200 patients at up to 30 investigative sites.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Over 21 years of age;
  • Capable and willing to give informed consent;
  • Acceptable candidate for an elective, non-emergent bronchoscopic procedure;
  • Lung lesions, 8 mm to 50 mm in size, requiring bronchoscopic diagnosis which were identified on thin slice CT scan within 28 days of the intended bronchoscopy

Exclusion criteria

  • Medical contraindication to bronchoscopy as assessed by the investigator
  • Presence of uncorrectable bleeding disorders
  • Medical devices interfering with electro-magnetic navigation, including but not limited to pacemaker
  • Patients with the target lesion having endobronchial involvement seen on chest CT
  • Lack fitness to undergo flexible bronchoscopy as determined by the bronchoscopist prior to procedure,
  • Participation in any other clinical trial within 30 days of enrollment that would interfere with this study;
  • Uncontrolled or irreversible coagulopathy;
  • Female subjects who are pregnant or nursing at the time of the procedure or those of child-bearing potential refusing a pregnancy test prior to the procedure;
  • CT scan done greater than 28 days before the bronchoscopy procedure.

Treatment and study plan

Robotic assisted bronchoscopy

Device

Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.

Other names: Robotic assisted bronchoscopy with Monarch platform

Primary outcomes

  1. Incidence of device or procedure related complications

    Time frame: up to 7 days post procedure

    The primary endpoint is a composite that includes pneumothorax requiring intervention rated as > Grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE) scale, bleeding requiring medical intervention, rated as > Grade 1 according to the CTCAE scale, and respiratory failure, rated as > Grade 3 according to the CTCAE scale.

Secondary outcomes

  1. Rate of device or procedure related complications

    Time frame: up to 7 days post procedure

    Individual components of the primary endpoint

  2. Rate of all pneumothoraxes

    Time frame: up to 7 days post procedure

  3. Total procedure time

    Time frame: During the procedure

  4. Rate of conversion to conventional bronchoscopic procedure

    Time frame: During the procedure

  5. Rate of adverse events unrelated to device or procedure

    Time frame: up to 7 days post procedure

  6. Stage at diagnosis

    Time frame: up to 24 months post procedure

    Stage at diagnosis (if applicable) will be evaluated for all robotic-assisted bronchoscopy procedures performed for suspicion of lung cancer

  7. Diagnostic yield

    Time frame: up to 24 months post procedure

    Diagnostic yield for all robotic-assisted procedure performed for suspicion of lung cancer will be evaluated based on histopathological assessment of acquired tissue samples

  8. Sensitivity for malignancy

    Time frame: up to 24 months post procedure

  9. Rate of post-bronchoscopy infections

    Time frame: up to 7 days post-procedure

Sponsors and collaborators

Lead sponsor

Auris Health, Inc.

Industry

Registry information

Official study title

Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors

Acronym: TARGET

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Dec 2, 2019
Registry last updated
Feb 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.